Adaptive Biotechnologies (ADPT) president sells $751k in stock

Adaptive Biotechnologies reported Q4 2025 EPS of -$0.09 vs consensus -$0.18 (50% positive surprise) and revenue $71.7M vs $59.33M (+20.85%), driving analysts to raise price targets (BTIG $22 from $21, TD Cowen $21 from $20; Piper Sandler reiterated $20 Overweight). President & COO Julie Rubinstein sold 57,180 shares between Mar 27-31, 2026 for total proceeds of ~$751,302 while exercising options to acquire 44,166 shares at $7.27; transactions executed under a Nov 18, 2025 Rule 10b5-1 plan and she now directly owns 455,878 shares. InvestingPro notes the stock is volatile, up ~86.81% over the past year but appears overvalued and the company is not forecast to be profitable this year.

Analysis

Adaptive’s strength in MRD testing creates leverage beyond headline revenue beats: as utilization migrates from one-off diagnostics to recurring post-treatment surveillance, per-test gross margins and revenue visibility both rise materially, improving free cash flow conversion over a 12–24 month window. A durable commercial lead also creates knock-on demand for upstream suppliers (sequencing reagents, sample logistics) and forces pricing/coverage conversations that could compress competitors’ margins even if absolute test volumes remain modest.

Key risks live at distinct horizons: idiosyncratic volatility and guidance updates will move the stock in days-to-weeks, payer policy and coverage decisions will dominate performance over 3–12 months, and true de-risking to sustained profitability requires 12–24 months of consistent MRD adoption and unit economics. Binary clinical/regulatory setbacks or a negative payer draft would likely trigger a rapid multiple reset — history suggests a 30–50% downside is possible on adverse developments, while positive national coverage decisions can compress time-to-profitability and expand upside.

The market currently prices both growth optionality and policy risk into the equity; that creates asymmetric trade opportunities. Near-term volatility makes defined-risk option structures attractive, while pairs can isolate commercial execution from sector-wide reimbursement shocks. Position sizing should reflect the dual realities of optional upside if MRD becomes standard-of-care and high short-term event risk from payers and guidance cycles.

Key Decisions for Investors

• Long ADPT equity (ticker: ADPT) on a 5–12% pullback from present levels; size 2–3% of portfolio, 12–18 month horizon. Target 40–80% upside if MRD adoption accelerates or national coverage emerges; hard stop at a 20% loss to limit event-driven downside.
• Buy a 9–12 month ADPT call spread (buy 25–35% OTM call, sell 60–80% OTM call) to capture optionality with defined downside. Position risk = premium paid; target 3x premium if a positive coverage/growth catalyst materializes within 9–12 months.
• Pair trade: long ADPT / short Guardant Health (GH) equal notional for 6–12 months to isolate company-specific commercial execution. Rationale: favor ADPT’s MRD commercialization cadence vs GH’s exposure; risk-management: tighten pair if relative moves exceed 15% against the position.
• Event-driven hedge: buy 3–6 month ADPT puts or short on any adverse CMS/payer draft or below-guidance quarter; keep sizing small (1% portfolio) as tactical insurance. Reward asymmetry is high because negative policy language typically drives large, rapid re-ratings.